10H-phenothiazine-1-carbonyl chloride | 17808-85-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 10H-phenothiazine-1-carbonyl chloride
• 英文别名: phenothiazin-10-ylcarbonylchloride；1-Chlorformyl-phenthiazin；10H-phenothiazine-1-carbonyl chloride
• CAS: 17808-85-4
• 化学式: C₁₃H₈ClNOS
• 分子量: 261.732
• InChiKey: BLDRISKODXTTQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  10H-phenothiazine-1-carbonyl chloride 在 palladium on barium sulfate 氢气 作用下， 以 甲苯 为溶剂， 反应 4.0h， 生成 1-formylphenothiazine
  参考文献：
  名称：

  Nealey,R.H.; Driscoll,J.S., Journal of Heterocyclic Chemistry, 1967, vol. 4, p. 587 - 590

  摘要：

  DOI：
• 作为产物：
  描述：

  10H-phenothiazine-1-carboxylic acid 在 草酰氯 作用下， 以 苯 为溶剂， 反应 4.0h， 生成 10H-phenothiazine-1-carbonyl chloride
  参考文献：
  名称：

  Nealey,R.H.; Driscoll,J.S., Journal of Heterocyclic Chemistry, 1967, vol. 4, p. 587 - 590

  摘要：

  DOI：

文献信息

• Treatment of diseases using ICE inhibitors
  申请人：Randle C.R. John

  公开号：US20050267101A1

  公开（公告）日：2005-12-01

  This invention relates to methods and compositions for treating autoinflammatory diseases. The invention also assays for evaluating the ability of an ICE inhibitor to treat autoinflammatory diseases.

  这项发明涉及用于治疗自身炎症性疾病的方法和组合物。该发明还涉及用于评估ICE抑制剂治疗自身炎症性疾病能力的检测方法。
• COLCHICINE DERIVATIVES
  申请人：——

  公开号：US20040204370A1

  公开（公告）日：2004-10-14

  Certain N-deacetylcolchicine and N-deacetylthiocolchine derivatives are described wherein the 7-N position on the B ring is substituted with the group —C(O)—(CHR 4 ) m -AR, wherein m is an integer of 0-10, A is S, O, N or a covalent bond; R 1 is substituted phenyl or substituted benzoyl; optionally substituted cycloalkyl of 3-7 carbons; optionally substituted naphtyl; an optionally substituted imide ring; an optionally substituted 5 or 6 member heterocycle with at least one N, S, or O in the ring; or an optionally substituted fused heterocyclic or fused carboxyclic ring system; R 2 (at the 2 -position of the A ring) is methoxy, hydroxy, or methylenedioxy when taken together with R 3 ; R 3 (at the 3 -position of the A ring) is methoxy, hydroxy, a monosaccharide radical, or is methylenedioxy when taken together with R 2 ; and R 4 is H or is H or methyl when m is 1. Also dimers of such compounds are disclosed. When combined with suitable pharmaceutical excipients, these compounds are useful for treating various types of cancer.

  描述了某些N-去乙酰基秋水仙碱和N-去乙酰基硫秋水仙碱衍生物，其中B环上的7-N位置被取代为基团—C(O)—(CHR4)m-AR，其中m为0-10的整数，A为S、O、N或共价键；R1为取代苯基或取代苯甲酰基；可选择取代的含有3-7个碳原子的环烷基；可选择取代的萘基；可选择取代的亚胺环；可选择取代的含有至少一个N、S或O的5或6元杂环；或可选择取代的融合杂环或融合环戊二酸环系统；R2（在A环的2位）为甲氧基、羟基或与R3一起时为亚甲二氧基；R3（在A环的3位）为甲氧基、羟基、单糖基团，或与R2一起时为亚甲二氧基；R4为H或在m为1时为H或甲基。此外，还公开了这些化合物的二聚体。与适当的药用辅料结合时，这些化合物可用于治疗各种类型的癌症。
• Caspase inhibitors and uses thereof
  申请人：——

  公开号：US20020058630A1

  公开（公告）日：2002-05-16

  Described herein are compounds that are useful as caspase inhibitors having the formula: 1 wherein Ring A is an optionally substituted piperidine, tetrahydroquinoline or tetrahydroisoquinoline ring; R 1 is hydrogen, CN, CHN 2 , R, or CH 2 Y; R is an optionally substituted group selected from an aliphatic group, an aryl group, or an aralkyl group; Y is an electronegative leaving group; R 2 is CO 2 H, CH 2 CO 2 H, or esters, amides or isosteres thereof; and R 3 is hydrogen, an optionally substituted aryl group, an optionally substituted aralkyl group, or an optionally substituted C 1-6 aliphatic group, R 4 is an optionally substituted group selected from an aryl group or a heterocyclyl group, or R 3 and R 4 taken together with the nitrogen to which they are attached optionally form a substituted or unsubstituted monocyclic, bicyclic or tricyclic ring.

  本文描述了作为caspase抑制剂有用的化合物，其化学式如下：其中环A是一个可选择取代的哌啶、四氢喹啉或四氢异喹啉环；R1是氢、CN、CHN2、R或CH2Y；R是从脂肪族群、芳香族群或芳基烷基群中选择的可选择取代的群；Y是电负离去基团；R2是CO2H、CH2CO2H或其酯、酰胺或同分异构体；R3是氢、一个可选择取代的芳基群、一个可选择取代的芳基烷基群或一个可选择取代的C1-6脂肪族群，R4是从芳基群或杂环基团中选择的可选择取代的群，或R3和R4连同它们附着的氮可选择形成一个取代或未取代的单环、双环或三环。
• Regulation of TNF-alpha
  申请人：——

  公开号：US20040048797A1

  公开（公告）日：2004-03-11

  The present invention relates to methods for identifying compounds useful for regulating TNF-alpha levels and/or activity. The invention also relates to methods for decreasing TNF-alpha levels and/or activity. Compounds and compositions according to this invention are useful for treating TNF-mediated diseases. The invention also relates to kits comprising the compounds and compositions herein and a tool for measuring TNF-alpha activity and/or levels.

  本发明涉及用于鉴定有用于调节TNF-alpha水平和/或活性的化合物的方法。本发明还涉及降低TNF-alpha水平和/或活性的方法。根据本发明的化合物和组合物对于治疗TNF介导的疾病是有用的。本发明还涉及包含本文所述的化合物和组合物以及用于测量TNF-alpha活性和/或水平的工具的试剂盒。
• TREATMENT OF DISEASES USING ICE INHIBITORS
  申请人：Randle John C.R.

  公开号：US20090192094A1

  公开（公告）日：2009-07-30

  This invention relates to methods and compositions for treating autoinflammatory diseases. The invention also assays for evaluating the ability of an ICE inhibitor to treat autoinflammatory diseases.

  本发明涉及治疗自身炎症性疾病的方法和组合物。本发明还涉及用于评估ICE抑制剂治疗自身炎症性疾病的方法。